Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background Opioid dependence is associated with low rates of treatment-seeking, poor adherence to treatment, frequent relapse, and major societal consequences. We aimed to assess the efficacy, safety, and patient-reported outcomes of an injectable, once monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) for treatment of patients with opioid dependence after detoxification.Methods We did a double-blind, placebo-controlled, randomised, 24-week trial of patients with opioid dependence disorder. Patients aged 18 years or over who had 30 days or less of inpatient detoxification and 7 days or more off all opioids were enrolled at 13 clinical sites in Russia. We randomly assigned patients (1:1) to either 380 mg XR-NTX or placebo by an interactive voice response system, stratified by site and gender in a centralised, permuted-block method. Participants also received 12 biweekly counselling sessions. Participants, investigators, staff , and the sponsor were masked to treatment allocation. The primary endpoint was the response profile for confirmed abstinence during weeks 5–24, assessed by urine drug tests and self report of non-use. Secondary endpoints were self-reported opioid-free days, opioid craving scores, number of days of retention, and relapse to physiological opioid dependence. Analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00678418.Findings Between July 3, 2008, and Oct 5, 2009, 250 patients were randomly assigned to XR-NTX (n=126) or placebo (n=124). The median proportion of weeks of confirmed abstinence was 90·0% (95% CI 69·9–92·4) in the XR-NTX group compared with 35·0% (11·4–63·8) in the placebo group (p=0·0002). Patients in the XR-NTX group self-reported a median of 99·2% (range 89·1–99·4) opioid-free days compared with 60·4% (46·2–94·0) for the placebo group (p=0·0004). The mean change in craving was –10·1 (95% CI –12·3 to –7·8) in the XR-NTX group compared with 0·7 (–3·1 to 4·4) in the placebo group (p<0·0001). Median retention was over 168 days in the XR-NTX group compared with 96 days (95% CI 63–165) in the placebo group (p=0·0042). Naloxone challenge confirmed relapse to physiological opioid dependence in 17 patients in the placebo group compared with one in the XR-NTX group (p<0·0001). XR-NTX was well tolerated. Two patients in each group discontinued owing to adverse events. No XR-NTX-treated patients died, overdosed, or discontinued owing to severe adverse events.Interpretation XR-NTX represents a new treatment option that is distinct from opioid agonist maintenance treatment. XR-NTX in conjunction with psychosocial treatment might improve acceptance of opioid dependence pharmacotherapy and provide a useful treatment option for many patients.Funding Alkermes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral naltrexone is ineffective in treating opiate addiction but recent studies using extended release naltrexone injections have shown promise.”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [118]
In the citing paper
“Patients receiving extended release naltrexone also had significantly fewer days of illicit opiate use.”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [118]
In the citing paper
“A larger trial in Russia retained 53% of patients at 6 months compared to 38% for placebo.”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [118]
In the citing paper
“Extended-release naltrexone gradually releases sufficient naltrexone to block the euphoric effects of opioids for approximately 1 month after injection and is efficacious as compared with placebo.9–12”
From Extended-release naltrexone to prevent opioid relapse in criminal justice offenders (2016) · cites this paper as [12]
In the citing paper
“Extended-release naltrexone gradually releases sufficient naltrexone to block the euphoric effects of opioids for approximately 1 month after injection and is efficacious as compared with placebo.9–12”
From Extended-release naltrexone to prevent opioid relapse in criminal justice offenders (2016) · cites this paper as [12]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Global tuberculosis control 2010
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262
Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome
Ball, J. C., & Ross, A. O. (1991) · Cited by 903
Research works printed but not linked: 1
- van der Waerden, 1953, Order tests for the two-sample problem. II, III, Proc K Ned Akad Wet A, 564, 303
Cited by
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
“Randomized controlled trials of oral and injectable naltrexone yielded retention rates greater than 50% at 6 months, which likely reflect the special characteristics of persons qualifying for these trials (8, 13).”
BackgroundLee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Self-citation
Metadata
- Authors
- Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L.
- Affiliations
- First Pavlov State Medical University of St. Petersburg (RU)
- New York State Psychiatric Institute (US)
- University of California, Los Angeles (US)
- Alkermes (United States) (US)
- Corresponding author
- Krupitsky, Evgeny
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 377
- Issue
- 9776
- Pages
- 1506-1513
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2164678034
- Cited by
- 555
- References
- 47
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 28 · 2023: 36 · 2022: 27 · 2021: 36 · 2020: 53 · 2019: 45 · 2018: 47 · 2017: 49 · 2016: 34 · 2015: 44 · 2014: 29 · 2013: 30 · 2012: 29
- FWCI
- 32.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Johns Hopkins University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, extended-release naltrexone, injectable naltrexone, opioid antagonists, opioid abstinence, opioid craving, relapse, treatment retention, opioid detoxification, patient-reported outcomes, opioid use disorder treatment, medication adherence, treatment-seeking behavior, harm reduction
- MeSH terms
- Adult, Delayed-Action Preparations, Double-Blind Method, Drug Administration Schedule, Female, HIV Seropositivity, Humans, Injections, Male, Naltrexone, Narcotic Antagonists, Opioid-Related Disorders, Substance Abuse Detection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(11)60358-9
- The paper
- Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(11)60358-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.